SG11201703550SA - Pharmaceutical composition comprising a beta blocker and an angiotensin converting enzyme inhibitor - Google Patents

Pharmaceutical composition comprising a beta blocker and an angiotensin converting enzyme inhibitor

Info

Publication number
SG11201703550SA
SG11201703550SA SG11201703550SA SG11201703550SA SG11201703550SA SG 11201703550S A SG11201703550S A SG 11201703550SA SG 11201703550S A SG11201703550S A SG 11201703550SA SG 11201703550S A SG11201703550S A SG 11201703550SA SG 11201703550S A SG11201703550S A SG 11201703550SA
Authority
SG
Singapore
Prior art keywords
pharmaceutical composition
converting enzyme
enzyme inhibitor
angiotensin converting
beta blocker
Prior art date
Application number
SG11201703550SA
Other languages
English (en)
Inventor
Gilles Fonknechten
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52345359&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201703550S(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of SG11201703550SA publication Critical patent/SG11201703550SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
SG11201703550SA 2014-11-05 2015-11-04 Pharmaceutical composition comprising a beta blocker and an angiotensin converting enzyme inhibitor SG11201703550SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1460654A FR3027803B1 (fr) 2014-11-05 2014-11-05 Composition pharmaceutique comprenant un betabloquant et un inhibiteur de l'enzyme de conversion
PCT/FR2015/052975 WO2016071631A1 (fr) 2014-11-05 2015-11-04 Composition pharmaceutique comprenant le bisoprolol et le périndopril

Publications (1)

Publication Number Publication Date
SG11201703550SA true SG11201703550SA (en) 2017-06-29

Family

ID=52345359

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201703550SA SG11201703550SA (en) 2014-11-05 2015-11-04 Pharmaceutical composition comprising a beta blocker and an angiotensin converting enzyme inhibitor
SG10201903656RA SG10201903656RA (en) 2014-11-05 2015-11-04 Pharmaceutical composition comprising a beta blocker and an angiotensin converting enzyme inhibitor

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201903656RA SG10201903656RA (en) 2014-11-05 2015-11-04 Pharmaceutical composition comprising a beta blocker and an angiotensin converting enzyme inhibitor

Country Status (24)

Country Link
EP (1) EP3215130B1 (es)
CY (1) CY1123322T1 (es)
DK (1) DK3215130T3 (es)
EA (1) EA032808B1 (es)
ES (1) ES2811904T3 (es)
FR (1) FR3027803B1 (es)
GE (1) GEP20196989B (es)
HR (1) HRP20201518T1 (es)
HU (1) HUE051947T2 (es)
LT (1) LT3215130T (es)
MA (1) MA40915B1 (es)
MX (1) MX2017005848A (es)
MY (1) MY187357A (es)
PH (1) PH12017500786B1 (es)
PL (1) PL3215130T3 (es)
PT (1) PT3215130T (es)
RS (1) RS60657B1 (es)
RU (1) RU2702362C2 (es)
SG (2) SG11201703550SA (es)
SI (1) SI3215130T1 (es)
TN (1) TN2017000170A1 (es)
UA (1) UA122131C2 (es)
WO (1) WO2016071631A1 (es)
ZA (1) ZA201703078B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2024004714A (es) 2021-10-20 2024-05-10 Servier Lab Nuevas sales de trimetazidina.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003092729A1 (de) 2002-05-03 2003-11-13 Hexal Ag Stabile pharmazeutische formulierung für eine kombination aus einem statin mit einem ace-hemmer
WO2007010501A2 (en) * 2005-07-22 2007-01-25 Ranbaxy Laboratories Limited A pharmaceutical composition comprising a combination of beta blocker and an ace inhibitor
HU230877B1 (hu) * 2008-09-30 2018-11-29 EGIS Gyógyszergyár NyR Stabil kombinációs gyógyszerkészítmény
AU2010242938A1 (en) * 2009-04-30 2011-11-17 Dr. Reddy's Laboratories Ltd. Fixed dose drug combination formulations
WO2011138772A1 (en) 2010-05-06 2011-11-10 Cal International Limited A pharmaceutical composition comprising aspirin and bisoprolol

Also Published As

Publication number Publication date
CY1123322T1 (el) 2021-12-31
HRP20201518T1 (hr) 2020-12-11
UA122131C2 (uk) 2020-09-25
ES2811904T3 (es) 2021-03-15
LT3215130T (lt) 2020-08-25
PH12017500786A1 (en) 2017-10-02
RU2017115341A (ru) 2018-11-05
WO2016071631A1 (fr) 2016-05-12
FR3027803A1 (fr) 2016-05-06
EA032808B1 (ru) 2019-07-31
SG10201903656RA (en) 2019-05-30
MA40915B1 (fr) 2020-08-31
MY187357A (en) 2021-09-22
EP3215130A1 (fr) 2017-09-13
PL3215130T3 (pl) 2020-11-16
EP3215130B1 (fr) 2020-07-08
SI3215130T1 (sl) 2020-11-30
PH12017500786B1 (en) 2017-10-02
PT3215130T (pt) 2020-08-26
MX2017005848A (es) 2017-06-27
FR3027803B1 (fr) 2018-02-09
GEP20196989B (en) 2019-07-10
EA201790772A1 (ru) 2017-09-29
HUE051947T2 (hu) 2021-03-29
DK3215130T3 (da) 2020-09-21
TN2017000170A1 (fr) 2018-10-19
ZA201703078B (en) 2020-11-25
RU2017115341A3 (es) 2019-05-21
RU2702362C2 (ru) 2019-10-08
RS60657B1 (sr) 2020-09-30

Similar Documents

Publication Publication Date Title
EP3193608A4 (en) Carm1 inhibitors and uses thereof
EP3193600A4 (en) Smyd inhibitors
EP3165965A4 (en) Photosensitive composition and compound
EP3331530A4 (en) Mthfd2 inhibitors and uses thereof
EP3246317A4 (en) Btk inhibitor
EP3116503A4 (en) Hptp-beta inhibitors
GB201421083D0 (en) Enzyme inhibitors
EP3193611A4 (en) Mk2 inhibitors and uses thereof
GB201421088D0 (en) New enzyme inhibitors
EP3302490A4 (en) AUTOTAXIN INHIBITORS AND USES THEREOF
IL246879B (en) Preparations of Epilimod and methods of using them
EP3341387A4 (en) SIALYLTRANSFERASE INHIBITORS AND USES THEREOF
EP3095076A4 (en) Complementary and shadow calendars
EP3302480A4 (en) Btk inhibitors
GB201421085D0 (en) New enzyme inhibitors
PT3334789T (pt) Composição anti-corrosão compreendendo pelo menos um primeiro composto e pelo menos um segundo composto
EP3362376A4 (en) DISTRIBUTOR AND SHIELD
HK1250926A1 (zh) 抑制劑及其應用
EP3191301A4 (en) Compositions and methods for fiber-containing grout
EP3247716A4 (en) Mir-92 inhibitors and uses thereof
EP3137629A4 (en) Compositions and methods for detecting huanglongbing
PT3202759T (pt) Derivado de alfa-aminoamida e composição farmacêutica contendo o mesmo
EP3185873A4 (en) Pharmaceutical composition and methods
EP3218373A4 (en) Anti-hcmv compositions and methods
EP3628374C0 (en) BCL-3 INHIBITORS